Taysha Gene Therapies Inc. (TSHA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TSHA scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental cash engine: 8 / 20. The rating cites ROIC of -35% and an FCF yield of -6.82%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it, so valuation depends on future cash flows that the source data does not project.
• Whale 13F flow: 5 / 20. The rating reflects institutional accumulation and options positioning. Because the holders section is empty in the source data, this pillar cannot be independently verified against named filers.
• Insider conviction: 3 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. The lower score signals weak insider-side confidence signals in the rating's inputs.
• Macro regime fit: 6 / 20. The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion.
• Forensic balance sheet: 11 / 20. The rating cites an Altman Z-Score of 5.67, a Piotroski F-Score of 4/9, and Debt/Equity of 0.2. The Z-Score is elevated, while the F-Score is weak; the balance sheet appears less stressed on leverage than on cash generation.

Taken together, the rating points to a company with a relatively strong balance sheet structure but weak operating economics. The upside case rests on a turnaround in cash generation that the source data does not quantify. The valuation tradeoff is that the stock trades at a $1.38B market capitalization against negative returns on capital, and the rating classifies it as an avoid.

Per the SEC financials, TSHA reported losses in each period shown, with operating margin at -60% and net margin at -60% in the market data. Gross margin is listed as 0%. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score is 5.67 and the Piotroski F-Score is 4/9, per the rating's forensic balance sheet pillar. Debt/Equity is 0.2. Reported cash rose from $139.0M to $319.8M between FY 2024 and FY 2025, while debt rose from $43.9M to $50.1M.

Per the recent news feed, the headlines center on valuation and price action rather than discrete corporate events. Items include a report that the stock may be above fair value on book value, a report of a 52-week low at 3.69 USD, a split valuation debate, an estimates page, a Simply Wall St note referencing early Rett data, and a report that the stock looks rich against book value. Most items are flagged YELLOW; one item is flagged GREEN with the CATALYST label. The 52-week low reference is a risk watch item given the current price of 4.22. The Rett data reference is a potential catalyst, but the source data does not provide the underlying results. Per the Butterfly Supply-Chain Graph, no proprietary signals are listed.

Per the Butterfly Supply-Chain Graph, supply chain: NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream or downstream dependencies. Sector correlation data is not provided beyond the beta of 1.0. Investors should watch for any second-order effects through the Health Care sector, but the source data does not identify specific bottlenecks.

• What are the underlying results of the early Rett data referenced in the news feed, and what is the timeline for further data?
• What revenue drivers produced the $9.8M in FY 2025, and what is the path to cash-flow breakeven?
• What drove the FY 2023 net loss of $-111.6M against an operating loss of $-72.4M, and what explains the missing FY 2023 cash and debt figures?
• What is the cash runway implied by the $319.8M cash balance against the FY 2025 FCF of $-93.8M?
• Who are the institutional and insider holders, given that the holders section is empty?